Tevimbra (tislelizumab-jsgr)

Adult Dosing .

Dosage forms:  INJ

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

esophageal CA, unresectable or metastatic

[PD-L1-expressing disease, first-line tx]

Dose: 150 mg IV q2wk; Alt: 200 mg IV q3wk or 300 mg IV q4wk or 400 mg q6wk; Info: for patients with squamous cell carcinoma; part of multi-drug chemo regimen

[previously treated disease]

Dose: 150 mg IV q2wk; Alt: 200 mg IV q3wk or 300 mg IV q4wk or 400 mg q6wk; Info: for patients with squamous cell carcinoma who have received prior tx other than PD-1/PD-L1 inhibitor

HER2-negative PD-L1-expressing gastric CA, unresectable or metastatic

[150 mg IV q2wk]

Alt: 200 mg IV q3wk or 300 mg IV q4wk or 400 mg q6wk; Info: for patients with gastric or gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1-3x ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.